SAB Biotherapeutics (NASDAQ:SABS) Stock Price Crosses Above 50-Day Moving Average – Should You Sell?

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) crossed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $3.26 and traded as high as $3.37. SAB Biotherapeutics shares last traded at $3.35, with a volume of 741,051 shares trading hands.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of SAB Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. Wall Street Zen raised shares of SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, August 10th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $12.00.

SAB Biotherapeutics Price Performance

The firm has a market capitalization of $304.80 million, a price-to-earnings ratio of -2.58 and a beta of 0.58. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average price of $3.26 and a two-hundred day moving average price of $3.68.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.28). As a group, research analysts forecast that SAB Biotherapeutics, Inc. will post -1.17 EPS for the current year.

Hedge Funds Weigh In On SAB Biotherapeutics

Several institutional investors have recently modified their holdings of SABS. IFP Advisors Inc bought a new stake in SAB Biotherapeutics in the 2nd quarter valued at about $151,000. Seven Fleet Capital Management LP raised its holdings in SAB Biotherapeutics by 47.2% during the second quarter. Seven Fleet Capital Management LP now owns 736,077 shares of the company’s stock worth $2,871,000 after purchasing an additional 236,077 shares in the last quarter. AWM Investment Company Inc. bought a new stake in shares of SAB Biotherapeutics in the 2nd quarter worth $1,462,000. Bank of New York Mellon Corp acquired a new stake in SAB Biotherapeutics in the 2nd quarter valued at about $421,000. Finally, DV Trading LLC bought a new stake in SAB Biotherapeutics during the first quarter worth approximately $1,532,000. Institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a biotechnology company focused on developing fully human polyclonal antibody medicines for infectious diseases, immune disorders and other conditions where targeted immune responses may provide therapeutic benefits. The company is based in Sioux Falls, South Dakota.

SAB Biotherapeutics uses its DiversitAb platform, which involves genetically engineered cattle capable of producing antibodies with human immune-system characteristics. Antibodies are collected from the animals’ plasma and processed for potential use as treatments, allowing the company to pursue antibody products without relying solely on conventional human donor sources.

The company has developed a pipeline that has included SAB-185, an investigational antibody therapy directed at SARS-CoV-2, as well as programs targeting influenza and autoimmune or immune-mediated diseases.